NEW YORK, New York — November 9, 2010 — HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (“HepaLife”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced a 510(k) submission to the FDA by its AquaMed Technologies, Inc. (“AquaMed”) subsidiary seeking pre-market clearance for its silver based antimicrobial wound dressing.

HepaLife intends for its silver based dressing, marketed under the Hydress +Plus™ brand name, to be an important addition to its existing wound care products. Silver, when moist, emits ions. Silver ions (Ag+) are bioactive and in sufficient concentration readily kill bacteria in both external wounds and in living tissue.  Upon approval, the Hydress +Plus™ silver based dressings are expected to be manufactured by AquaMed, yet marketed and sold through HepaLife’s recently formed Alliqua BioMedical, Inc. (“Alliqua”) subsidiary, which will also be responsible for selling and marketing HepaLife’s various other hyrdrogel products going forward.

“We believe that this product represents an important step forward in the field of advanced wound care, and one which has the potential to drive our business opportunities in the near term,” said Matt Harriton, CEO of Alliqua.  “The management team is committed to getting this product to market as quickly as possible while simultaneously developing strong distribution channels and marketing resources for its launch.”

Silver based wound dressings are becoming increasingly prevalent in wound care due to the recent increase of antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus, known as MRSA. The Company’s dressing is approximately 90% water based; hence, does not have the issues of requiring pre-wetting or absorption of transdermal water loss or wound exudate to become bioactive.

Mr. Harriton continued, “As the process for clearance takes place, we look forward to providing our shareholders with updates on this, as well as various other leading growth initiatives for our organization over the coming weeks and months.”

Management anticipates that the initial markets for the product will include diabetic ulcers, pressure sores, burns and post surgical applications. Management estimates that the number of diabetic ulcers in the U.S. is in excess of 2.5 million wounds and that there are over 30 million surgical procedures done in the US each year.

About HepaLife Technologies, Inc.

HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1), is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation.  Through its recently formed subsidiary, Alliqua BioMedical, Inc., HepaLife intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by HepaLife’s AquaMed Technologies, Inc. subsidiary.

AquaMed Technologies, Inc. (“AquaMed”), another wholly-owned subsidiary of HepaLife, manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two known manufacturers in the world for these gels.

HepaLife Technologies, Inc. is also the developer of HepaMate™, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. HepaMate™ is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. These components are assembled into a patented blood/plasma circulation system, which is placed on the HepaDrive™ perfusion platform.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.hepalife.com, and www.aquamedinc.com

To receive future press releases via email, please visit: http://www.hepalife.com/investor_alerts.php

To view the full HTML text of this release, please visit: http://www.hepalife.com/press_releases/20101109-1.html.php

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components,  inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Contact:

HepaLife Technologies, Inc.

Ben Mayer

215-970-7193

NEW YORK, New York — November 3, 2010 — HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (“HepaLife”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced its intention to pursue the development of a transdermal pain patch.  HepaLife’s subsidiary, Alliqua BioMedical, Inc. (“Alliqua”), recently retained Jeiven Pharmaceutical Consulting, Inc. (“Jeiven”) to assist it in this new product development.

Through this partnership, Alliqua intends to aggressively pursue a generic version of an existing pain management patch for the treatment of postherpetic neuralgia (“PHN”).  PHN is associated with shingles, which is a rising medical problem in the United States and around the world as countries continue to struggle with increasingly elderly populations.

“We believe that our existing expertise in manufacturing these products, combined with the developmental and regulatory experience that Jeiven brings to this project will prove invaluable, and will help us realize commercialization in a timely and cost effective manner,” said Matthew Harriton, CEO of Alliqua. “Utilizing HepaLife’s proprietary hydrogel technology, we believe Alliqua can become a high quality, low cost producer of this transdermal pain patch.”

“We are excited to join the Alliqua team in this project. Alliqua benefits from an extensive knowledge base and a proven expertise in manufacturing specialty medical products including components for transdermal patches,” said Ashutosh Sharma, PhD, Vice President and Chief Scientific Officer at Jeiven. “By combining Jeiven’s extensive resources and decades of experience in pharmaceutical product development, with HepaLife’s proprietary technology, we believe Alliqua has a great opportunity for a relatively low risk product launch with the possibility for significant gain in market share.”

Management estimates that the total U.S. market for pain management pharmaceuticals, exclusive of over-the-counter products, totaled in excess of $20 billion in 2009, with the market for the existing prescription pain patch in excess of $1 billion in the US alone. According to the Centers for Disease Control, approximately 1 million cases of shingles occur in the United States annually, and approximately 20% of shingles cases result in PHN. HepaLife’s patch technology enables the delivery of drugs and active ingredients directly through the stratum corneum avoiding ‘first pass’ of the digestive system and the liver.

About Jeiven Pharmaceutical Consulting, Inc.

Jeiven Pharmaceutical Consulting, Inc. (“JPC”) brings over twenty years of experience to the goal of providing pharmaceutical, biotechnology, medical device and dietary supplement companies with expert service and dedication to ensure the success of their projects. JPC and its divisions provide a broad range of consulting services ranging from product development, GXP audits, preparation of regulatory filings (INDs, NDAs, 510(k)s etc.), Clinical Supplies project management, GXP and DEA training seminars, Quality Assurance / Quality Control support, and Clinical Trials Management. JPC also sponsors the Clinical Supplies Support Group (CSSG), which it founded in 1995, and which provides a forum for the discussion of issues related to Clinical Supplies manufacture, testing, packaging, labeling, distribution, and reconciliation.

About HepaLife Technologies, Inc.

HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1), is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation.  Through its recently formed subsidiary, Alliqua BioMedical, Inc., HepaLife intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by HepaLife’s AquaMed Technologies, Inc. subsidiary.

AquaMed Technologies, Inc. (“AquaMed”), another wholly-owned subsidiary of HepaLife, manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two known manufacturers in the world for these gels.

HepaLife Technologies, Inc. is also the developer of HepaMate™, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. HepaMate™ is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. These components are assembled into a patented blood/plasma circulation system, which is placed on the HepaDrive™ perfusion platform.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.hepalife.com, and www.aquamedinc.com

To receive future press releases via email, please visit: http://www.hepalife.com/investor_alerts.php

To view the full HTML text of this release, please visit: http://www.hepalife.com/press_releases/20101103-1.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, litigation and administrative proceedings, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of our operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in our equity, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission along with our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 17, 2010. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. We undertake no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

HepaLife Technologies, Inc.
Ben Mayer
215-970-7193

NEW YORK, New York — November 1, 2010 — HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (“HepaLife”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announces the formation of a new wholly owned subsidiary, Alliqua BioMedical, Inc. (“Alliqua”).Alliqua intends to develop, manufacture and market its own proprietary products, utilizing HepaLife’s existing technology portfolio.  It further intends to pursue projects in the fields of active ingredient and transdermal drug delivery, as well as advanced wound care.

In connection with the formation of Alliqua, HepaLife appointed Matt Harriton as Alliqua’s CEO. Mr. Harriton brings over 23 years of experience across a range of industries and applicable fields, including SEC compliance, FDA compliance and intellectual property rights.

“The launch of Alliqua marks a significant milestone for HepaLife and its shareholders,” said Matt Harriton, CEO of Alliqua. “Leveraging HepaLife’s proprietary technology and proven expertise, Alliqua represents the expansion of HepaLife’s business into the mutli-billion dollar drug delivery and advanced wound care markets.”

In conjunction with the formation of Alliqua, HepaLife reiterates its major milestones over the past year:

• Through the acquisition of AquaMed Technologies, Inc. and its hydrogel technology platform in May 2010, HepaLife has expanded its business focus to include the multi-billion dollar fields of transdermal drug and actives delivery, with added applications in wound care, medical diagnostics, consumer health and cosmetics.
• HepaLife’s private placement in May 2010 has helped secure its financial position and provides it with a greater ability to execute its strategic initiatives.

“We are pleased to announce the formation of Alliqua, as we believe it will drive HepaLife’s existing and developmental product pipeline going forward,” said Richard Rosenblum, President of HepaLife.  “As we proactively penetrate the expanding drug delivery and wound care industries, we remain highly committed to growing our revenue, earnings and, ultimately, shareholder value.”

HepaLife’s modern 16,500 square foot cGMP compliant facility in Langhorne, Pennsylvania, is crucial in helping Alliqua meet its strategic growth objectives and provides a significant barrier to entry for other manufacturers.  The facility, which is operated by another HepaLife subsidiary, AquaMed Technologies, Inc., manufactures a highly specialized aqueous hydrogel designed for various healthcare sectors, including: wound care, medical diagnostics, drug delivery, cosmetics and patient management. AquaMed is one of only two known manufacturers of this type of gel in the world and its manufacturing facility is FDA registered.

About HepaLife Technologies, Inc.

HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1), is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation.  Through its recently formed subsidiary, Alliqua BioMedical, Inc., HepaLife intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by HepaLife’s AquaMed Technologies, Inc. subsidiary.

AquaMed Technologies, Inc. (“AquaMed”), another wholly-owned subsidiary of HepaLife, manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels.

HepaLife Technologies, Inc. is also the developer of HepaMate™, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. HepaMate™ is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. These components are assembled into a patented blood/plasma circulation system, which is placed on the HepaDrive™ perfusion platform.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.hepalife.com, and www.aquamedinc.com

To receive future press releases via email, please visit: http://www.hepalife.com/investor_alerts.php

To view the full HTML text of this release, please visit: http://www.hepalife.com/press_releases/20101101-1.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, litigation and administrative proceedings , the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of our operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in our equity, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission along with our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 17, 2010. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. We undertake no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

HepaLife Technologies, Inc.
Ben Mayer
215 970 7193

New York, NY – May 17^th, 2010 - HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), on May 11, 2010, HepaLife Technologies, Inc., a Florida corporation (“HepaLife”), consummated a merger (the “Merger”) whereby HepaLife acquired all of the issued and outstanding common and preferred shares of AquaMed Technologies, Inc., a privately held Delaware corporation (“AquaMed”) in exchange for 84.8 million shares of HPLF common stock. As a result of the Merger, AquaMed became a wholly-owned subsidiary of HepaLife.

Additionally, HepaLife consummated private placements on May 11, 2010 of 9,400,000 units  of its securities and on May 14, 2010 of 2,000,000 units of its securities at a price of $0.125 per unit and received aggregate gross proceeds of $ $1,425,000. Each unit consisted of (i) one (1) share of HepaLife Common Stock, (ii) one half of one five year Series E Stock Purchase Warrant  with an exercise price of $0.16 per share, and (iii) one half of one five year Series F Stock Purchase Warrant  with an exercise price of $0.20 per share.

Palladium Capital Advisors, LLC served as the sole placement agent for the private placements, and acted as advisor to HepaLife for the Merger.

As a result of the transaction, effective May 11, 2010, Amit S. Dang resigned as President and CEO of HepaLife. Richard Rosenblum assumed the title of President of HepaLife and David Stefansky became its Chairman. Matthew Harriton will serve as CEO of the AquaMed subsidiary. Amit Dang commented, “We believe that the acquisition of AquaMed with its proven delivery platform and experienced management team will enable the company to continue to build shareholder value and advance the commercialization of the HepaMate^TM product.”

ABOUT AQUAMED TECHNOLOGIES, INC.

AquaMed develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics.  These gels are produced using unique proprietary manufacturing technologies which enable AquaMed to develop, manufacture and market electron beam cross-linked aqueous polymer sheet hydrogels.  AquaMed is believed to be one of two known manufacturers in the world of these gels. AquaMed specializes in custom hydrogels capitalizing on proprietary manufacturing technologies.

ABOUT HEPALIFE TECHNOLOGIES, INC.

HepaLife Technologies, Inc. (OTCBB: HPLF – News) (FWB: HL1) (WKN: 500625) is the developer of HepaMate™ an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. HepaMate™ is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. These components are assembled into a patented blood/plasma circulation system, which is placed on the HepaDrive™ perfusion platform. There are currently no cell-based liver support systems commercially available or in Phase III clinical trials in the US or Europe.

The HepaMate™ technology is believed by HepaLife to be one of the most clinically studied bioartificial liver in the world, tested in clinical studies involving more than 200 patients with over 50 scientific papers and book chapters published on the technology.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:

http://www.hepalife.com/investor_alerts.php

To view the full HTML text of this release, please visit:

http://www.hepalife.com/press_releases/20100517-1.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although HepaLife believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of HepaLife’s products, technical problems with the HepaLife’s research and products, price increases for supplies and components, litigation and administrative proceedings involving the HepaLife, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the HepaLife’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the HepaLife’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in HepaLife’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission along with HepaLife’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 17, 2010. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. HepaLife undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances

Other big news includes the introduction of conductive adhesive manufacturing to our product line. Commonly used for TENS electrodes, EEG, and other medical monitoring applications, these hydrogel formulations are prepared with an electrolyte (salt) formula that can be adjusted to vary the level of electrical conductivity desired. Because hydrogel patches naturally adhere to the skin, they create good electrical contact without aggressively adhering to the skin as some other chemical adhesives can. Therefore, they’re easier to remove and more comfortable for the patient.

Hydrogel TENS electrodes

Contact us now for information on our newest electrode gel for use with TENS electrodes. Available now in conductive and nonconductive versions.